Keith R Loeb
Overview
Explore the profile of Keith R Loeb including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
4477
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Le Q, Hadland B, Smith J, Leonti A, Huang B, Ries R, et al.
J Clin Invest
. 2024 Aug;
134(16).
PMID: 39145456
No abstract available.
2.
Menssen A, Hudson C, Alonzo T, Gerbing R, Pardo L, Leonti A, et al.
Haematologica
. 2024 Feb;
109(10):3182-3193.
PMID: 38299667
As curative therapies for pediatric acute myleoid leukemia (AML) remain elusive, identifying potential new treatment targets is vital. We assessed the cell surface expression of CD74, also known as the...
3.
Guerriero M, Ally F, Loeb K, Nair V
BMC Pulm Med
. 2023 Oct;
23(1):391.
PMID: 37845664
Background: Immunosuppressed bone marrow transplant patients with pulmonary infiltrates routinely undergo bronchoscopy with bronchoalveolar lavage (BAL) to investigate potential etiologies. Cytokine release syndrome after BAL is unreported in the literature...
4.
Loeb A, Pattwell S, Meshinchi S, Bedalov A, Loeb K
Blood Adv
. 2023 Jun;
7(19):5851-5859.
PMID: 37315172
Hematopoietic stem cell transplantation is a well-known treatment for hematologic malignancies, wherein nascent stem cells provide regenerating marrow and immunotherapy against the tumor. The progeny of hematopoietic stem cells also...
5.
Le Q, Tang T, Leonti A, Castro S, McKay C, Perkins L, et al.
Blood Adv
. 2023 Jan;
7(9):1666-1670.
PMID: 36595452
No abstract available.
6.
Pattwell S, Arora S, Nuechterlein N, Zager M, Loeb K, Cimino P, et al.
Sci Adv
. 2022 Oct;
8(40):eabo6789.
PMID: 36206341
Temporally regulated alternative splicing choices are vital for proper development, yet the wrong splice choice may be detrimental. Here, we highlight a previously unidentified role for the neurotrophin receptor splice...
7.
Targeting FOLR1 in high-risk CBF2AT3-GLIS2 pediatric AML with STRO-002 FOLR1-antibody-drug conjugate
Tang T, Le Q, Castro S, Pardo L, McKay C, Perkins L, et al.
Blood Adv
. 2022 Sep;
6(22):5933-5937.
PMID: 36149945
No abstract available.
8.
Le Q, Hadland B, Smith J, Leonti A, Huang B, Ries R, et al.
J Clin Invest
. 2022 Sep;
132(22).
PMID: 36136600
The CBFA2T3-GLIS2 (C/G) fusion is a product of a cryptic translocation primarily seen in infants and early childhood and is associated with dismal outcome. Here, we demonstrate that the expression...
9.
Kirkey D, Loeb A, Castro S, McKay C, Perkins L, Pardo L, et al.
Blood Adv
. 2022 Aug;
7(7):1178-1189.
PMID: 35984639
Preferentially Expressed Antigen in Melanoma (PRAME), a cancer-testis antigen, provides an ideal target for immunotherapy in acute myeloid leukemia (AML). We have shown expression of PRAME in a significant subset...
10.
Manson M, Zhang F, Novokhodko A, Chen C, Parker M, Loeb K, et al.
Blood Adv
. 2022 Apr;
6(12):3557-3568.
PMID: 35427415
A safe, effective, and inclusive gene therapy will significantly benefit a large population of patients with hemophilia. We used a minimally invasive transcutaneous ultrasound-mediated gene delivery (UMGD) strategy combined with...